---
schema_version: "secwatch.filing_event.v1"
accession: "0001001233-26-000005"
form_type: "8-K"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-02-03T23:59:59+00:00"
generated_at: "2026-05-16T05:12:54.258604+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Sangamo: ST-920 Phase 1/2 data positive; FDA agrees to Accelerated Approval path

## Summary
- FDA agreed Phase 1/2 STAAR data can support Accelerated Approval using eGFR slope at 52 weeks; rolling BLA started Dec 2025.
- Positive mean annualized eGFR slope of 1.965 at Week 52 (95% CI -0.153, 4.083) across 32 patients; Week 104 slope 1.747.
- All 15 ERT-naïve patients achieved normal/supraphysiological α-Gal A activity up to 54 months; 18 ERT patients safely withdrew from ERT.
- 32 of 33 patients completed 52-week follow-up; ST-920 well-tolerated with no discontinuations due to AEs, no TMA or complement activation.
- Statistically significant improvements in SF-36 QoL and GSRS diarrhea scores at Week 52; anti-α-Gal A antibodies reduced/eliminated in 9/10 patients.

## SEC filing metadata
- accession: 0001001233-26-000005
- form_type: 8-K
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-02-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000100123326000005/0001001233-26-000005-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000100123326000005/sgmo-20260203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001001233-26-000005
- JSON: https://secwatch.observer/filing/0001001233-26-000005.json
- Plain text: https://secwatch.observer/filing/0001001233-26-000005.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.